SEATTLE, Wa., January 6, 2017 - Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces it has entered into an agreement with Amgen to further develop and commercialize Adaptive’s NGS-based clonoSEQ Assay to assess minimal residual disease (MRD) in patients with Acute Lymphoblastic Leukemia (ALL).
BREAKING NEWS FROM ADAPTIVE
SEATTLE, WA, June 27, 2013 – Adaptive Biotechnologies announced today that they have signed an agreement with Biogen Idec for the study of the immune repertoire and the search for immunological biomarkers in difficult to treat autoimmune diseases.
STOCKHOLM – Sequenta, Inc. announced today that its collaborators will present studies at the 18th Congress of the European Hematology Association (EHA) here this week demonstrating the superiority of the company’s LymphoSIGHT™ technology in detecting minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and multiple myeloma (MM).
CEO and co-founder Chad Robins will join a distinguished panel of leaders in the biotech and pharmaceuticals industries to discuss personalized medicine in healthcare at the Boston CEO Conference at the Four Seasons Hotel Boston.
CHICAGO – Researchers from Hospital Universitario 12 de Octubre presented data today at the American Society of Clinical Oncology Annual Meeting (ASCO) that demonstrated the power of Sequenta’s LymphoSIGHT™ platform for the detection of minimal residual disease (MRD) in multiple myeloma patients. The oral presentation described how researchers compared Sequenta’s proprietary sequencing method with other technologies for assessing MRD levels following standard therapy.
Adaptive announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology. Under the collaboration, Adaptive will use its proprietary immune profiling assay, immunoSEQ, to identify potential biomarkers that may inform about drug response.
Xconomy Seattle’s biotech conference, “Biotech in the Belt-Tightening Era,” held on April 9 featured many biotech industry leaders including Adaptive’s CEO Chad Robins. The conference dealt with the issue of rising healthcare costs and its impact on biotech companies and their ability to fund research for new drugs and diagnostics.
The April 11th issue of Nature magazine featured an article highlighting the importance of finding immunological markers for immunotherapy drugs and cell therapy approaches for cancer.
On March 27, the New England Journal of Medicine published an article (click to download PDF) that highlights the clinical relevance of MRD monitoring by Next Generation Sequencing and its potential superiority to flow cytometry – concluding a wave of impactful articles this month supporting the launch of Adaptive’s clonoSEQ MRD technology.
SEATTLE, WA, March 4, 2013 – Adaptive Biotechnologies Corporation, a leading provider of next-generation sequencing assays for the adaptive immune system, selected today four recipients to receive its Young Investigator Award for February. Winners will receive a $5,000 grant to use towards the purchase of immunoSEQ assays as part of their research in a variety of fields, such as immunology.